INTERVENTION 1:	Intervention	0
HER2 Therapies, Cardiac Medications	Intervention	1
Cardiac intervention - beta-blockers and ACE-inhibitors titrated to the maximum tolerated doses	Intervention	2
Oncology intervention - patients will receive one of the three following HER2 targeted therapies at the discretion of the treating oncologist:	Intervention	3
Trastuzumab: loading dose of 8 mg/kg IV, followed by a maintenance dose of 6 mg/kg every 3 weeks, or a loading dose of 4 mg/kg followed by a maintenance dose of 2 mg/kg every week.	Intervention	4
week	UO:0000034	91-95
week	UO:0000034	175-179
Pertuzumab: loading dose of 840 mg IV, followed by 420 mg IV every 3 weeks, administered concomitantly with trastuzumab.	Intervention	5
Ado trastuzumab emtansine (TDM1): 3.6mg/kg IV every three weeks.	Intervention	6
Trastuzumab: HER2 therapy	Intervention	7
Pertuzumab: HER2 therapy	Intervention	8
Ado Trastuzumab Emtansine: HER2 therapy	Intervention	9
Inclusion Criteria:	Eligibility	0
Female or male patient diagnosed with stage I-IV breast cancer	Eligibility	1
female	PATO:0000383	0-6
male	CHEBI:30780,PATO:0000384	2-6
male	CHEBI:30780,PATO:0000384	10-14
patient	HADO:0000008,OAE:0001817	15-22
breast cancer	DOID:1612	49-62
HER2 positive breast cancer, defined by immunohistochemical staining for HER2 protein of 3+ intensity and/or amplification of the HER2 gene on fluorescence in situ hybridization (FISH)  2.0 on breast specimen or biopsy of a metastatic site	Eligibility	2
breast cancer	DOID:1612	14-27
protein	CHEBI:36080,BAO:0000175	78-85
intensity	PATO:0000049	92-101
gene	BAO:0000582	135-139
breast	UBERON:0000310	14-20
breast	UBERON:0000310	193-199
site	BFO:0000029	235-239
LVEF < 50% and  40% documented in echocardiogram done within the last 30 days	Eligibility	3
HER2 therapy naÃ¯ve or currently receiving non-lapatinib HER2 targeted therapy	Eligibility	4
Patient receiving or planning to receive trastuzumab, trastuzumab with pertuzumab or ado-trastuzumab emtansine, for at least 3 months, alone or in combination with other systemic treatment or radiation	Eligibility	5
patient	HADO:0000008,OAE:0001817	0-7
Age  18 years	Eligibility	6
age	PATO:0000011	0-3
Patient is willing and able to comply with protocol required assessments and procedures	Eligibility	7
patient	HADO:0000008,OAE:0001817	0-7
Exclusion Criteria:	Eligibility	8
Previous hospitalization due to documented heart failure in the last 12 months	Eligibility	9
heart	UBERON:0000948	43-48
Current signs or symptoms of heart failure or ischemia	Eligibility	10
heart	UBERON:0000948	29-34
ischemia	DOID:326	46-54
History of arrhythmia requiring pharmacological or electrical treatment	Eligibility	11
history	BFO:0000182	0-7
arrhythmia	HP:0011675	11-21
Concomitant use of anthracyclines or use of anthracyclines in the last 50 days	Eligibility	12
Pregnant or lactating patients. Patients of childbearing potential must implement contraceptive measures during study treatment and for 7 months after last dose of treatment drug and must have negative urine or serum pregnancy test within 7 days prior to registration.	Eligibility	13
drug	CHEBI:23888	174-178
urine	UBERON:0001088	202-207
History of significant neurologic or psychiatric disorders including psychotic disorders or dementia that would prohibit the understanding and giving of informed consent.	Eligibility	14
history	BFO:0000182	0-7
dementia	HP:0000726,DOID:1307	92-100
Outcome Measurement:	Results	0
Percentage of Patients Who Complete Planned Oncologic Therapy Without the Development of a Cardiac Event or Asymptomatic Worsening of Cardiac Function.	Results	1
function	BAO:0003117,BFO:0000034	142-150
Cardiac events are defined as any of the following:	Results	2
Presence of symptoms attributable to heart failure as confirmed by a cardiologist	Results	3
heart	UBERON:0000948	37-42
Cardiac arrhythmia requiring pharmacological or electrical treatment	Results	4
arrhythmia	HP:0011675	8-18
Myocardial infarction	Results	5
myocardial infarction	HP:0001658,DOID:5844	0-21
Sudden cardiac death or death due to myocardial infarct, arrhythmia or heart failure	Results	6
sudden cardiac death	HP:0001645	0-20
death	OAE:0000632	15-20
death	OAE:0000632	24-29
arrhythmia	HP:0011675	57-67
heart	UBERON:0000948	71-76
Asymptomatic worsening of cardiac function defined as:	Results	7
function	BAO:0003117,BFO:0000034	34-42
- Asymptomatic decline in LVEF > 10% points from baseline and/or EF < 35% corroborated by a confirmatory echocardiogram in 2-4 weeks	Results	8
Planned oncologic therapy is defined as:	Results	9
In the adjuvant setting: completion of 1 year total of HER2 targeted therapy. If a patient already received part of the planned HER2 targeted therapy prior to enrollment in this trial, planned oncologic therapy will be achieved when a total of 1 year is completed.	Results	10
adjuvant	CHEBI:60809	7-15
year	UO:0000036	41-45
year	UO:0000036	246-250
patient	HADO:0000008,OAE:0001817	83-90
part of	BAO:0090002,BFO:0000050	108-115
In the metastatic setting: cessation of treating regimen due to progressive disease or non-cardiac toxicity or non-cardiac death.	Results	11
progressive	HP:0003676	64-75
disease	DOID:4,OGMS:0000031	76-83
death	OAE:0000632	123-128
Time frame: Up to 18 months.	Results	12
time	PATO:0000165	0-4
Results 1:	Results	13
Arm/Group Title: HER2 Therapies, Cardiac Medications	Results	14
Arm/Group Description: Cardiac intervention - beta-blockers and ACE-inhibitors titrated to the maximum tolerated doses	Results	15
Oncology intervention - patients will receive one of the three following HER2 targeted therapies at the discretion of the treating oncologist:	Results	16
Trastuzumab: loading dose of 8 mg/kg IV, followed by a maintenance dose of 6 mg/kg every 3 weeks, or a loading dose of 4 mg/kg followed by a maintenance dose of 2 mg/kg every week.	Results	17
week	UO:0000034	91-95
week	UO:0000034	175-179
Pertuzumab: loading dose of 840 mg IV, followed by 420 mg IV every 3 weeks, administered concomitantly with trastuzumab.	Results	18
Ado trastuzumab emtansine (TDM1): 3.6mg/kg IV every three weeks.	Results	19
Trastuzumab: HER2 therapy	Results	20
Pertuzumab: HER2 therapy	Results	21
Ado Trastuzumab Emtansine: HER2 therapy	Results	22
Overall Number of Participants Analyzed: 30	Results	23
Measure Type: Count of Participants	Results	24
Unit of Measure: Participants  27  90.0%	Results	25
Adverse Events 1:	Adverse Events	0
Total: 3/30 (10.00%)	Adverse Events	1
Cardiac event 3/30 (10.00%)	Adverse Events	2
